Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

ClinicalTrials.gov ID: NCT02411539

Public ClinicalTrials.gov record NCT02411539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults

Study identification

NCT ID
NCT02411539
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
40 participants

Conditions and interventions

Conditions

Interventions

  • VRC01 Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 24, 2015
Primary completion
Apr 14, 2016
Completion
Sep 28, 2016
Last update posted
Nov 4, 2021

2015 – 2016

United States locations

U.S. sites
13
U.S. states
13
U.S. cities
13
Facility City State ZIP Site status
UCSD Antiviral Research Center CRS San Diego California 92103
University of Colorado Hospital CRS Aurora Colorado 80045
Northwestern University CRS Chicago Illinois 60611
Johns Hopkins University CRS Baltimore Maryland 21205
Massachusetts General Hospital CRS (MGH CRS) Boston Massachusetts 02114
Washington University Therapeutics (WT) CRS St Louis Missouri 63110-1010
University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester New York 14642
Chapel Hill CRS Chapel Hill North Carolina 27599
Ohio State University CRS Columbus Ohio 43210
University of Pittsburgh CRS Pittsburgh Pennsylvania 15213
Vanderbilt Therapeutics (VT) CRS Nashville Tennessee 37204
Houston AIDS Research Team CRS Houston Texas 77030
University of Washington AIDS CRS Seattle Washington 98104-9929

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02411539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02411539 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →